Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor - Dutasteride.

CONCLUSION: We did not find consistent evidence of a significant association between dutasteride therapy and the risk of cardiovascular adverse events.
PMID: 23815285 [PubMed - as supplied by publisher]

Source: Clinical Prostate Cancer - July 1, 2013 Category: Cancer & Oncology Authors: Loke YK, Ho R, Smith M, Wong O, Sandhu M, Sage W, Singh S Tags: J Clin Pharm Ther Source Type: research